Glaxosmithkline Plc Adr Stock Profit Margin
| GSK Stock | USD 38.95 0.55 1.43% |
GlaxoSmithKline PLC's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting GlaxoSmithKline Stock price.
GlaxoSmithKline | Profit Margin | Build AI portfolio with GlaxoSmithKline Stock |
GlaxoSmithKline PLC ADR Company Profit Margin Analysis
GlaxoSmithKline PLC's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current GlaxoSmithKline PLC Profit Margin | 0.10 % |
Most of GlaxoSmithKline PLC's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
GlaxoSmithKline Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for GlaxoSmithKline PLC is extremely important. It helps to project a fair market value of GlaxoSmithKline Stock properly, considering its historical fundamentals such as Profit Margin. Since GlaxoSmithKline PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GlaxoSmithKline PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GlaxoSmithKline PLC's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, GlaxoSmithKline PLC ADR has a Profit Margin of 0.1%. This is 100.89% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The profit margin for all United States stocks is 107.87% lower than that of the firm.
GlaxoSmithKline Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.GlaxoSmithKline PLC is currently under evaluation in profit margin category among its peers.
GlaxoSmithKline Fundamentals
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0655 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.31 % | ||||
| Current Valuation | 97.6 B | ||||
| Shares Outstanding | 2.02 B | ||||
| Shares Owned By Institutions | 18.19 % | ||||
| Number Of Shares Shorted | 16.48 M | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 4.01 X | ||||
| Price To Sales | 2.49 X | ||||
| Revenue | 31.38 B | ||||
| Gross Profit | 22.67 B | ||||
| EBITDA | 6.67 B | ||||
| Net Income | 2.95 B | ||||
| Cash And Equivalents | 3.72 B | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 16.99 B | ||||
| Debt To Equity | 0.98 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 3.47 X | ||||
| Cash Flow From Operations | 6.55 B | ||||
| Short Ratio | 3.41 X | ||||
| Earnings Per Share | 2.09 X | ||||
| Price To Earnings To Growth | 0.37 X | ||||
| Target Price | 41.72 | ||||
| Number Of Employees | 68.63 K | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 78.46 B | ||||
| Total Asset | 59.46 B | ||||
| Retained Earnings | 7.8 B | ||||
| Working Capital | (4.7 B) | ||||
| Current Asset | 16.59 B | ||||
| Current Liabilities | 13.42 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 5.32 % | ||||
| Net Asset | 59.46 B | ||||
| Last Dividend Paid | 0.62 |
About GlaxoSmithKline PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.547 | Dividend Share 0.62 | Earnings Share 2.09 | Revenue Per Share 15.448 | Quarterly Revenue Growth 0.021 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.